Vergleich

Ladostigil (hemitartrate) Europäischer Partner

ArtNr HY-10400-50mg
Hersteller MedChem Express
CAS-Nr. 209394-46-7
Menge 50 mg
Quantity options 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Kategorie
Typ Molecules
Specific against other
Purity 98.90
Citations [1]Denya I, et, al. Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer's disease. Medchemcomm. 2018 Jan 16;9(2):357-370.
[2]Weinreb O, et, al. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
[3]Weinstock M, et, al. Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression. J Neural Transm Suppl. 2006;(70):443-6.
[4]Poltyrev T, et, al. Effect of chronic treatment with ladostigil (TV-3326) on anxiogenic and depressive-like behaviour and on activity of the hypothalamic-pituitary-adrenal axis in male and female prenatally stressed rats. Psychopharmacology (Berl). 2005 Aug;181(1):118-25.
Smiles O=C(OC1=CC2=C(CC[C@H]2NCC#C)C=C1)N(CC)C.OC([C@H](O)[C@@H](O)C(O)=O)=O.[1/2]
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Alias TV-3326 (hemitartrate)
Versandbedingung Raumtemperatur
Lieferbar
Manufacturer - Type
Reference compound
Manufacturer - Applications
Neuroscience-Neurodegeneration
Manufacturer - Targets
Cholinesterase (ChE); Monoamine Oxidase
Shipping Temperature
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Molecular Weight
694.77
Product Description
Ladostigil (TV-3326) hemitartrate is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC50s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hemitartrate exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil hemitartrate can be used for the research of depression and Alzheimer's disease[1][2]. Ladostigil (hemitartrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Manufacturer - Research Area
Neurological Disease
Solubility
H2O : 60 mg/mL (ultrasonic; warming)|DMSO : 50 mg/mL (ultrasonic)
Manufacturer - Pathway
Neuronal Signaling
Isoform
MAO-B
Clinical information
Phase 2

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 50 mg
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen